C12N 2760/14234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14234 (Use of virus or viral component as vaccine) appears on 35 US grants and 57 published applications in this corpus.
Search patents in C12N- Granted patents
- 35
- Published applications
- 57
- Assignees
- 41
- Inventors
- 108
- Latest grant
- 29 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 2 | 2 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 2 | 3 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 1 | 8 |
| 2018 | 1 | 5 |
| 2019 | 0 | 3 |
| 2020 | 7 | 8 |
| 2021 | 5 | 4 |
| 2022 | 4 | 4 |
| 2023 | 6 | 3 |
| 2024 | 3 | 4 |
| 2025 | 2 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)29 Jul 2025US 12,370,249 B2GeoVax, Inc.
- Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same8 Apr 2025US 12,268,735 B2The Trustees of the University of Pennsylvania
- Reverse peptide vaccine3 Dec 2024US 12,156,909 B2Emergex Vaccines Holding Ltd.
- Methods and compositions for inducing protective immunity against filovirus infection5 Mar 2024US 11,918,639 B2Bavarian Nordic A/S
- Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40)13 Feb 2024US 11,896,657 B2GeoVax, Inc.
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Thermostable mucosal vaccine compositions and methods12 Feb 2026US 2026/0041757 A1Global Health Solutions LLC
- Vesicular stomatitis virus marburg virus vaccine2 Oct 2025US 2025/0302896 A1International AIDS Vaccine Initiative
- Ebolavirus and marburgvirus vaccines5 Sep 2024US 2024/0293526 A1CureVac AG
- Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines13 Jun 2024US 2024/0189413 A1Soligenix, Inc.
Most cited
By later US patents
- Genetic induction of anti-viral immune response and genetic vaccine for filovirus34US 6,200,959 B1PowerJect Vaccines Inc. · 2001
- Generation of virus-like particles and use as panfilovirus vaccine20US 7,682,618 B2The United States of America as represented by the Secretary of the Army · 2010
- Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same10US 9,597,388 B2The Trustees of the University of Pennslyvania · 2017
- Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers7US 8,012,489 B22011
- Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same4US 10,034,930 B2The Trustees of the University of Pennsylvania · 2018